Poultry probiotic vaccine compositions and methods of use thereof

Provided herein are compositions including a probiotic including at least one strain of live bacteria and a Marek\u27s Disease vaccine. Compositions including a probiotic or a probiotic and a Marek\u27s Disease vaccine may be administered to subjects, including poultry. The compositions may be administered in ovo to increase early lactic acid bacteria in the gastrointestinal tract of the subject, to decrease the gram negative bacteria in the gastrointestinal tract of the subject, to reduce the level of Salmonella in the gastrointestinal tract of the subject and to increase the body weight gain of the subject. Also provided are kits including a probiotic and a Marek\u27s Disease vaccine

Yeast Vaccine Vector Including Immunostimulatory And Antigenic Polypeptides And Methods Of Using The Same

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided

Method to reduce microbial bloom in poultry hatchery

Spore forming bacteria and Lactic Acid Bacteria for application in poultry hatcher cabinets to alter the bacterial bloom towards a more beneficial microbiota, positively affecting performance parameters such as mortality, body weight gain and feed conversion ratio throughout production

Method to reduce microbial bloom in poultry hatchery

Spore forming bacteria and Lactic Acid Bacteria for application in poultry hatcher cabinets to alter the bacterial bloom towards a more beneficial microbiota, positively affecting performance parameters such as mortality, body weight gain and feed conversion ratio throughout production

Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector

Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector

Compositions and methods of enhancing immune responses to enteric pathogens

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide

Compositions and Methods of Enhancing Immune Responses to Eimeria or Limiting Eimeria Infection

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or morality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector